Gene test could help young women with uterine cancer preserve fertility

NCT ID NCT06799624

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at 100 women aged 18-45 with early-stage endometrial cancer who want to preserve their fertility. Researchers will analyze the tumor's molecular subtype (based on gene testing) to see how it affects response to hormone therapy and recurrence rates. The goal is to better predict which patients are good candidates for fertility-sparing treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which women with endometrial cancer are most likely to benefit from fertility-sparing hormone therapy, enabling more personalized treatment decisions.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients, and the sample size is modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

    Milan, Michigan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.